Gouty Arthritis (Gout) Pipeline Review H2 2015

1. Gouty Arthritis (Gout) - Pipeline Review, H2 2015 By RnRMarketResearch.com Publisher Name : Global Markets Direct Date: 30-Nov-2015 No. of pages: 117 Single User License: US $2000 Browse more Reports on Arthritis therapeutics at http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=449114 . ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

2. Gouty Arthritis (Gout) - Pipeline Review, H2 2015 This report provides comprehensive information on the therapeutic development for Gouty Arthritis (Gout), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gouty Arthritis (Gout) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

3. Gouty Arthritis (Gout) - Pipeline Review, H2 2015 Companies Discussed/Mentioned in this Research: AstraZeneca Plc, Celtaxsys, Inc., CymaBay Therapeutics, Inc., Delenex Therapeutics AG, Immune Response BioPharma, Inc., IOmet Pharma, JW Pharmaceutical Corporation, LG Life Science LTD., Monosol Rx, LLC, Nimbus Therapeutics, LLC, Omni Bio Pharmaceutical Inc., Opsona Therapeutics Limited, PLx Pharma Inc., Polaris Pharmaceuticals, Inc., Selecta Biosciences, Inc., Takeda Pharmaceutical Company Limited, Teijin Limited, TWi Pharmaceuticals, Inc. and Wellstat Therapeutics Corporation Drugs Profile Discussed in this Research: acebilustat, arhalofenate, AXIBU-03, colchicine, diacerein, DLX-2323, DLX-2681, FcAAT-2, FcAAT-3, febuxostat, febuxostat XR, IR-888, LC-350189, lesinurad sodium, Moniclonal Antibody to Inhibit S100A9 Protein for Neurodegenerative Diseases, Chronic Inflammation and Autoimmune Disorders, ND-2110, ND-2158, ND-346, pegadricase, PL-4100, RDEA-3170, Recombinant Enzyme for Gout and Tumor Lysis Syndrome, Recombinant Protein to Replace Alpha-1 Antitrypsin Cardiovascular, Metabolic Disorders, Immunology, Gastrointestinal Disease, RLBN-1001, RLBN-2020 Series, RLBN-3010 Series, Small Molecule Inflammasome Modulator Programme, Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia, Small Molecules to Inhibit GLUT9 for Gout, URC-102, uriSHELS, WT-2107, XEN-102 and XEN-104 ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

4. Gouty Arthritis (Gout) - Pipeline Review, H2 2015 Scope For Gouty Arthritis (Gout) - Pipeline Review, H2 2015 • The report provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout) • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved in the therapeutics development for Gouty Arthritis (Gout) and enlists all their major and minor projects • The report summarizes all the dormant and discontinued pipeline projects • A review of the Gouty Arthritis (Gout) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages • A detailed assessment of monotherapy and combination therapy pipeline projects • Coverage of the Gouty Arthritis (Gout) pipeline on the basis of target, MoA, route of administration and molecule type • Latest news and deals relating related to pipeline products ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

5. Gouty Arthritis (Gout) - Pipeline Review, H2 2015 Reasons to Buy: • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Develop strategic initiatives by understanding the focus areas of leading companies • Identify and understand important and diverse types of therapeutics under development for Gouty Arthritis (Gout) • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline • Devise corrective measures for pipeline projects by understanding Gouty Arthritis (Gout) pipeline depth and focus of Indication therapeutics • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

6. Gouty Arthritis (Gout) - Pipeline Review, H2 2015 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441